The agreement also includes an additional contingent consideration of about $350m based on achievement of certain sales milestones
The acquisition will give AMAG access to Lumara’s Makena, the only approved product designed to reduce the risk of preterm birth in women who are pregnant with one baby and who have delivered one preterm baby spontaneously in the past.
According to the company, net sales of Makena over the 12 months ending 31 August 2014 were greater than $130m, a 72% increase compared to the same period last year.
AMAG president and chief executive officer William Heiden said the company the Lumara Health transaction will facilitate future product acquisitions in an attractive new therapeutic area and is an excellent strategic fit with its Feraheme market expansion plans.
Heiden added: "The consequences of preterm birth are a significant public health issue, and we believe that Makena will be a tremendous addition to our portfolio and will be complementary to AMAG’s in-office injectables commercial expertise.
"We believe that our combined larger scale, combined portfolio diversification, new resources and broader commercial expertise will allow AMAG to create new long-term growth opportunities and allow us to better serve patients."
Seperately, Lumara has signed an agreement to divest certain other assets of its portfolio of women’s health products to Perrigo for $82m.
The acquired portfolio generated over $15m in net revenues during the twelve months ended 31 March 2014.